Stoke Therapeutics Files 2025 Proxy Statement
Ticker: STOK · Form: DEF 14A · Filed: Apr 22, 2025 · CIK: 1623526
| Field | Detail |
|---|---|
| Company | Stoke Therapeutics, Inc. (STOK) |
| Form Type | DEF 14A |
| Filed Date | Apr 22, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, annual-meeting
TL;DR
Stoke Therapeutics DEF 14A filed 4/22 for 6/3 meeting - proxy details, director votes, exec pay.
AI Summary
Stoke Therapeutics, Inc. filed its definitive proxy statement on April 22, 2025, for its annual meeting of stockholders scheduled for June 3, 2025. The filing details the company's governance, executive compensation, and proposals to be voted on by shareholders. Key items likely include the election of directors and ratification of independent auditors.
Why It Matters
This filing provides shareholders with crucial information regarding company leadership, compensation, and voting matters, enabling informed participation in corporate governance.
Risk Assessment
Risk Level: low — DEF 14A filings are routine disclosures and do not inherently represent new risks.
Key Numbers
- 20250422 — Filing Date (Date the definitive proxy statement was filed.)
- 20250603 — Meeting Date (Date of the annual meeting of stockholders.)
Key Players & Entities
- Stoke Therapeutics, Inc. (company) — Registrant
- 45 WIGGINS AVENUE, BEDFORD, MA 01730 (address) — Business and Mail Address
- 0001193125-25-089188 (filing_id) — Accession Number
- 20250422 (date) — Filing Date
- 20250603 (date) — Meeting Date
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or Definitive Proxy Statement, is used by companies to solicit proxies from shareholders for an upcoming meeting, providing detailed information on matters to be voted upon, such as director elections and executive compensation.
When is Stoke Therapeutics' annual meeting of stockholders?
Stoke Therapeutics' annual meeting of stockholders is scheduled for June 3, 2025.
What is the filing date of this proxy statement?
This definitive proxy statement was filed on April 22, 2025.
What is the company's primary business classification?
Stoke Therapeutics, Inc. is classified under Pharmaceutical Preparations (SIC code 2834).
Where is Stoke Therapeutics, Inc. located?
Stoke Therapeutics, Inc. is located at 45 Wiggins Avenue, Bedford, MA 01730.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 22, 2025 regarding Stoke Therapeutics, Inc. (STOK).